Skip to main content


Argonne maintains a wide-ranging science and technology portfolio that seeks to address complex challenges in interdisciplinary and innovative ways. Below is a list of all articles, highlights, profiles, projects, and organizations related specifically to biology.

Filter Results

  • A low-cost process that accelerates biological methane production rates at least fivefold
    Intellectual Property Available to License

    US Patent 8,247,009
    • Enhanced Renewable Methane Production System Benefits Wastewater Treatment Plants, Farms, and Landfills (ANL-IN-05-079)

    The Invention 

    Process schematic of Argonne’s Enhanced Renewable Methane Production System.

    Argonne’s Enhanced Renewable Methane Production System provides a low-cost process that accelerates biological methane production rates at least fivefold. The innovative system addresses one of the largest barriers to expanding the use of renewable methane — the naturally slow rate of production. To overcome this challenge, Argonne researchers examined the natural biology of methane production, the natural processes for carbon dioxide (CO2) sequestration, and the environmental quality of the water found in coal bed methane wells. Their research led to the novel, low-cost treatment that enhances the heating value of biogas, delivering a gas that is close to pipeline quality. This system offers an improved means of producing biological methane at wastewater treatment plants, farms, and landfills. 

    Argonne’s system also simultaneously sequesters the CO2 produced during the process by reacting with magnesium and calcium silicate rocks. This innovation links the biological conversion (renewable carbon source being converted to methane and carbon dioxide) to a geochemical mechanism (producing solid carbonate-enriched minerals), thus eliminating CO2 emissions. 

    Argonne’s Enhanced Renewable Methane Production System can accelerate biological methane production rates at least fivefold.


    • Produces near-pipeline-quality methane 
    • Enables simultaneous carbon dioxide sequestration

    Applications and Industries

    • Wastewater treatment plants 
    • Recovery of methane from manure and agricultural processing 
    • Recovery of methane from food processing wastes 
    • Methane from other carbonaceous feedstock. 

    Developmental Stage 

    Reduction to practice testing is complete. Researchers are now working on prototype-scale testing with field testing to follow. 

  • Transportation fuel and organic solid fertilizer from anaerobic digestion of wastewater solids and other organic wastes
    Intellectual Property Available to License
    US Patent 9,994,870
    • Method for generating methane from a carbonaceous feedstock

    The Innovation

    The biogas made from biosolids generated at wastewater treatment plants in the anaerobic digesters (ADs) contains high amounts of CO2 and hydrogen sulfide (H2S), and other gases as impurities that reduce its utility. H2S is corrosive at very low levels. In order to make biogas usable as a transportation fuel, its methane content must be enriched to the level found in natural gas by depleting CO2; and H2S levels must also be reduced. Researchers have made various previous attempts to separate CO2 in biogas production systems and thus enrich the methane content in biogas. However, among the disadvantages of this approach are that the H2S must be removed separately. Most of these methods are not economical, because post-production processing of biogas is required.

    Previously, researchers at Argonne National Laboratory had developed processes for in situ treatment of ADs to enrich the methane content in biogas to the levels found in natural gas. First, the Argonne researchers used pulverized rocks rich in CaCO3 and MgCO3 that sequesters the CO2 (background patent 8,247,009). The pulverized rocks were placed in the AD in removable mesh buckets. However, such rocks must be mined, pulverized, and transported, each of which adds costs.

    Argonne researchers next used a locally available agricultural by-product, biochar (charcoal), in the ADs and achieved reduction of both CO2 and H2S, with in situ sequestration of carbon, and methane enrichment of biogas to the pipeline-quality level of natural gas with >85% methane. Biochars from various sources perform similarly in methane enrichment in biogas. It is possible that some geographic regions may have biochar sources that may be functionally equivalent to the biochars used in Argonne studies and industrial-scale pilot testing.

    The biochar used thus far by Argonne is rich in divalent and monovalent cations, calcium, potassium, and magnesium, which has increased these cations in the digestate that can be used as organic solid fertilizer—leading to a significant revenue stream. Chemical analysis reveals that organic solid fertilizer is rich in nitrogen, phosphorous, potassium, and sulphur.

    Developmental Stage

    Pilot-scale process evaluation performed at a third-party site.

    Availability/Commercial Readiness

    Ready for development under a research partnership

  • Efficient biofuels for the next generation
    Intellectual Property Available to License

    US Patent Application 2011/0302830
    • Biofuels from Photosynthetic Bacteria (ANL-IN-09-001)

    The Innovation

    Production of fuels from renewable energy sources can address many important national and global issues. Rising energy costs and the uncertainty in supply of crude oil have the ability to affect national security. Rising CO2 levels resulting from the world’s thirst for liquid fuels pose substantial climate and ecosystem threats.

    Photosynthetic bacteria can be a renewable source of fuel molecules. The photosynthetic machinery in these highly pigmented bacteria includes cofactors (chlorophyll, carotenoids, quinones, etc.) that are anchored in the proteins by long hydrocarbon tails. These anchors can be used directly as fuel substitutes once they are separated from the bacteria that produced them. They are more compatible with modern engines than are molecules that comprise current-day biodiesel formulations (sourced from plant fatty acids). In this alternative approach to efficient production of next-generation biofuels, Argonne researchers have engineered photosynthetic bacteria and developed specific Rhodobacter strains and processes that mass produce the fuel molecules (such as phytol, shorter isoprenols, and other atypical alcohols) and export them from the cell to be separated and used directly as fuel in compression-ignited (diesel) engines. The molecules require no further chemical upgrading for use.

    Schematic of the overall approach including the method for production of biofuels

    The Rhodobacter species of photosynthetic bacteria are facultative and are frequently known to bloom in animal waste lagoons in the summer in the Midwest. This versatility, as such, can be exploited for adaptation of their growth to whatever feedstocks are prevalent in local areas. More than 115 engineered Rhodobacter strains are under evaluation at Argonne, and a variety of screening methodologies has allowed selection of strains that are relatively omnivorous with respect to the nutrient and energy requirements used for conversion processes (e.g., the use of light). Depending upon the type of separations process used downstream for recovery, fuel molecules can be secreted into the fermentation broth or internalized as storage reserves for later harvest and extraction from bacterial cell pellets.

    Argonne is pursuing industrial partnerships to scale and commercialize this technology.

    The Benefits

    The Rhodobacter strains developed at Argonne have the following benefits over traditional approaches:

    • Flexibility: the engineered bacteria produce biofuels using a variety of growth modes (including photosynthetic) and can thrive on carbon sources available in most areas. 
    • Versatility: the bacteria can grow on waste materials (carbon and water) not currently used for food or as feedstocks for other processes. 
    • Simplicity: Direct production is realized by single-celled organisms exporting product into the culture medium. 
    • Compatibility: the biofuels produced can be consumed as is” or mixed with other fuels without the need for refining (cracking) or distillation. 
    • Transportability: Rhodobacter fuel bioreactors can be set up at any (including those seemingly most remote) location(s) for production of liquid fuel or for conversion in diesel generators to produce electricity on demand. 
    • Sustainability: 30–70% of waste from the new process consists of lipids, which can be modified to produce conventional biodiesel. 

    Application and Industries

    • Transportation sector
    • Waste-to-energy facilities
    • Remote operations requiring liquid fuels or electricity

    Developmental Stage

    Experimental-scale production of biofuel achieved; ready for scale up.

    Availability/Commercial Readiness

    Available for licensing and scale up or further development to focus on production of specialized fuels or chemicals.

  • A unique system for membrane protein expression makes it possible to obtain reasonable yields of functional membrane protein
    Intellectual Property Available to License
    US Patent 6,465,216; US Patent 8,455,231; US Patent Application 2014/0080176
    • A System for Expression of Membrane Proteins (ANL-IN-06-099)

    The Innovation

    Cell membranes are the interface between an organism and its environment. These biological structures contain proteins that are extremely important for many cellular processes (e.g., nutrient uptake, metabolic waste excretion, energy metabolism, and response to external stimuli). Because of their mediating roles between external stimuli and internal cellular metabolism, membrane proteins account for more than 60% of drug targets.

    Schematic of the overall approach that excels in the overproduction of membrane proteins

    Membrane proteins, however, present unique challenges because they are hydrophobic, which means they are highly unstable and insoluble in the aqueous environments typically used to produce and characterize hydrophilic proteins. It is therefore difficult to produce and purify them in quantities and at a level of quality sufficient for conducting structural or functional studies. That is also why the number of unique membrane protein structures determined to date lags far behind the number of those known for water-soluble proteins.

    There are few available systems that enable heterologous expression of membrane proteins. Most were adapted from soluble protein expression systems and usually present challenges for research projects working on membrane proteins. For example, such systems using E. coli often produce insoluble aggregates or cause host toxicity as membrane space is limited. Alternatively, eukaryotic expression systems are costly and cumbersome to implement.

    In contrast, a unique system for membrane protein expression invented by Philip Laible and Deborah Hanson in the Biosciences Division at Argonne National Laboratory makes it possible to obtain reasonable yields of functional membrane protein. This proprietary method uses photosynthetic bacteria (Rhodobacter) for the expression of heterologous membrane proteins.

    Rhodobacter cells produce extremely large amounts of intracellular membrane when cultured under certain conditions.Synthesis of foreign (or native) membrane proteins and this intracellular membrane can be coordinated in these bacteria. Partial purification of the expressed membrane proteins is afforded because they are sequestered in these membrane vesicles, which are easily separated by size. Vesicles enriched in target membrane proteins can be used directly in many types of activity assays. Recently, work with the Rhodobacter expression system has become less cumbersome by additional engineering of strains that allow the direct uptake of foreign DNA (patent application pending). Previous methods used a two-step process: foreign DNA was first introduced into E. coli cells, which were then mated with Rhodobacter cells – mobilizing and transferring the foreign DNA by a process known as conjugation. Rhodobacter strains can now be manipulated using common laboratory methods (e.g., chemical or electroporetic transformation).

    The Benefits

    This method offers such advantages as lower production costs, ease of purification, scalability, and high yields of membrane proteins (0.5 mg/L to as high as 20 mg/L culture). The system permits the simultaneous production and sequestration of foreign membrane proteins, yielding a higher fraction of proteins in soluble form, as well as avoiding toxicity to the host. It has strong applications in both the pharmaceutical and biotechnology industries. As biologics become more mainstream, large quantities of active membrane proteins will be required for regulatory testing. Certain membrane proteins of therapeutic importance have been overexpressed with success, and research is under way to validate the method further for other classes of industrially relevant membrane proteins.

    Application and Industries

    • A research tool for expression of challenging proteins
    • Scaled production for biologics testing and drug discovery efforts

    Publication Information

    P. D. Laible et al., J. Struct. Funct. Genomics 5: 167–172 (2004)

    Developmental Stage

    Ready for commercialization

  • A process for amorphous pharmaceuticals
    Intellectual Property Available to License
    US Patent 9,327,264 B2
    • Containerless synthesis of amorphous and nanophase organic materials

    The Invention 

    (a) Acoustic levitator levitating several samples simultaneously (shown as white spheres) with a 14mm spacing. Illustrations on

    Making fast-acting pharmaceuticals is a goal of almost every drug company. The route of delivering pharmaceuticals in the form of amorphous solids has long been recognized as a possible way to improve dissolution rates and to increase both solubility and bioavailability. Development in this direction is becoming increasingly important due to the emergence of many new drugs that are virtually insoluble in their crystalline form. Researchers at Argonne National Laboratory have developed the technique of acoustic levitation to prepare amorphous solids and molecular gels that can be easily applied to the pharmaceutical manufacturing process. This technique would improve the solubility and bioavailability of several drugs. 

    The acoustic levitation techniques developed at Argonne keeps the drug solution from making contact with any surface whatsoever during the solvent evaporation process. This containerless process was developed and tested on several over-the-counter and prescription pharmaceuticals. Several of the pharmaceuticals amorphized using the Argonne process remained completely amorphous for four months or longer. Please review the publication for additional details.


    A containerless process: 

    • Precludes the possibility of a drug’s interaction with its container; 
    • Provides a more effective means of synthesizing amorphous pharmaceutical compounds; 
    • Offers higher yields than current state-of-the-art methods; 
    • Reduces the potential for contamination during the manufacturing process; and 
    • Is expected to advance the development of amorphous drug forms, increasingly important due to new drugs that are virtually insoluble in crystalline form.

    Applications and Industries 

    Pharmaceutical industry 

    Developmental Stage 

    Proof of principle 

  • Thermal tomography is used to create three-dimensional images of skin damage due to radiation treatment
    Intellectual Property Available to License

    US Patent 7,365,330; US Patent 7,538,938
    • Three-Dimensional Thermal Tomography (3DTT) Advances Cancer Treatment (ANL-IN-06-017)

    The method allows more rapid, yet still non-invasive, detection and is expected to enhance the treatment experience for breast cancer patients. 

    Background and Need 

    Change in temperature over time (left) is used to calculate the 3-dimensional effusivity distribution (right). Each slice repres

    Because cancer cells grow more quickly than healthy cells, they are typically a few degrees higher in temperature. This attribute makes it possible to use thermal imaging to detect them. For this reason, passive thermal imaging is helpful in detecting breast cancer. In active thermal imaging, heat or cold is applied to an object and an infrared camera is used to observe the resulting temperature change. 

    Thermal imaging can be used to analyze even multilayered materials— making the methodology even more useful than conventional processes like X-rays, CT and ultrasonic scanning for such applications. 

    The Invention 

    A team of researchers from Rush University Medical Center and Argonne National Laboratory is using a 3-D technique to detect early skin changes due to radiation treatment in breast cancer patients. Use of the technique could facilitate earlier delivery of treatment to prevent radiation skin damage in these patients. They can develop a skin reaction that, in severe cases, causes discomfort and can disrupt therapy. However, if detected early, skin reactions are preventable or treatable. 

    Clinical tests used 3DTT to measure the skin’s thermal effusivity—a tissue property that quantifies its ability to exchange heat with its surroundings. In the test, a flash of filtered light heats the skin while an infrared camera captures a time series of images that display skin temperatures by color. Using an algorithm to calculate temperature changes and determine the thermal effusivity at different skin depths, the researchers discovered the effusivity values of damaged skin tissue differ from that of healthy skin. 

    Preliminary data show that marked reductions in the effusivity levels of irradiated skin occur well in advance of development of high-grade skin reactions. Soon, the team hopes to apply the 3DTT technique in breast cancer patients. Also underway is the development of an even more sophisticated algorithm to improve resolution at subsurface depths.


    Three-dimensional thermal tomography offers significant benefits over existing technologies: 

    • Is non-invasive and enhances healing. 
    • Measures tissue property changes without interrupting treatment. 
    • Provides rapid feedback to clinicians during diagnosis and treatment. 
    • Detects other conditions, such as skin cancer, where changes in effusivity would enable researchers to locate and quantify the number of cancer cells. 
    • Measures skin damage caused by electricity or lightning and to evaluate the progress of skin grafts. 
    • Applicable to virtually any material up to about 10 millimeters deep. 
    • Enables clinicians to image multilayered materials without knowing the number of layers in advance, unlike other imaging technologies. 
    • Offers higher spatial resolution compared to that of other technologies such as X-rays, CT, and ultrasound. 

    Applications and Industries 

    The 3DTT technique has wide application in medicine as well as in other industries where in situ inspection is required, such as the imaging of engine components or the space-shuttle thermal protection system. 

    Developmental Stage 

    This technology is ready for prototype development.